SGHT

Sight Sciences, Inc. · NASDAQ

Sector Health Technology
Industry Medical Specialties
Website ightsciences.com
Employees(FY) 250
ISIN US82657M1053

Performance

-4.03%

-5.31%

-48.26%

-44.22%

-30.81%

YTD

+7.21%

Profile

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.

Advanced Technical Analysis

Technical Analysis of SGHT 2024-12-20

The stock exhibits a bearish sentiment overall, with a Moving Average Score of 10 indicating strong downward pressure, while the Oscillators Score of 63 suggests some bullish momentum. However, the Technical Score of 36 reinforces the bearish outlook, indicating that the stock may face challenges in sustaining upward movement in the near term.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of SGHT

Stock Rank

Recent News & Updates

2024-12-19 03:05
Sight Sciences Announces the Results of a Budget Impact Analysis for its TearCare System for the Treatment of Meibomian Gland Disease ( MGD ) Showing Cost Savings Over Existing Reimbursed Treatment Options(Globenewswire)
2024-12-06 16:31
Sight Sciences initiated with a Buy at UBS(Yahoo Finance)
2024-11-19 03:05
Sight Sciences to Present at the Piper Sandler 36th Annual Healthcare Conference(Globenewswire)
2024-11-17 21:00
Inside a $400 billion bet on the brain-computer interface revolution(Yahoo Finance)
2024-11-11 17:50
Sight Sciences price target lowered to $5 from $7 at Morgan Stanley(Yahoo Finance)
2024-11-07 17:02
Sight Sciences Inc (SGHT) Q3 2024 Earnings Call Highlights: Navigating Challenges with ...(Yahoo Finance)
2024-11-07 06:05
Sight Sciences, Inc. (SGHT) Reports Q3 Loss, Misses Revenue Estimates(Yahoo Finance)
2024-11-07 03:05
Sight Sciences Reports Third Quarter 2024 Financial Results and Updates its Full Year 2024 Adjusted Operating Expense Guidance(Yahoo Finance)
2024-11-07 03:04
Sight Sciences Appoints MK Raheja as Executive Vice President, Research and Development and Brenton Taylor as Executive Vice President, Operations(Globenewswire)
2024-11-05 18:43
Sight Sciences Inc (SGHT) Q3 2024 Earnings Report Preview: What To Expect(Yahoo Finance)
2024-10-17 04:05
Sight Sciences to Report Third Quarter Financial Results on November 7, 2024(Globenewswire)
2024-10-14 04:05
Single TearCare Treatment Improved Functional Visual Outcomes as well as Signs and Symptoms of Patients with Dry Eye Disease in Investigator-Initiated Trial(Globenewswire)
2024-08-20 21:36
AmEx downgraded, Texas Instruments upgraded: Wall Street's top analyst calls(Yahoo Finance)
2024-08-20 04:05
Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference(Globenewswire)
2024-08-01 23:30
Q2 2024 Sight Sciences Inc Earnings Call(Yahoo Finance)
2024-08-01 06:45
Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates(Yahoo Finance)
2024-08-01 04:05
Sight Sciences Reports Second Quarter 2024 Financial Results and Narrows Full Year 2024 Financial Guidance(Globenewswire)
2024-07-18 04:05
Sight Sciences to Report Second Quarter Financial Results on August 1, 2024(Globenewswire)
2024-06-10 04:05
Sight Sciences Announces the Release of its First Sustainability Report(Globenewswire)
2024-05-28 04:05
Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis(Globenewswire)
2024-05-27 20:30
Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI Across Mild, Moderate, and Advanced Glaucoma(Globenewswire)
2024-05-07 04:05
Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference(Globenewswire)
2024-05-05 22:02
Sight Sciences, Inc. (NASDAQ:SGHT) Q1 2024 Earnings Call Transcript(Yahoo Finance)
2024-05-03 01:37
Sight Sciences Shares Up After Q1 Net Loss Narrows, Revenue Rises; 2024 Revenue Outlook Reaffirmed(Yahoo Finance)
2024-05-03 01:04
Q1 2024 Sight Sciences Inc Earnings Call(Yahoo Finance)
2024-05-02 09:55
SGHT Stock Earnings: Sight Sciences Misses EPS, Beats Revenue for Q1 2024(Investorplace)
2024-05-02 06:20
Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Tops Revenue Estimates(Zacks)
2024-05-02 04:05
Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance(Globenewswire)
2024-04-29 23:02
Sight Sciences awarded $34m in Alcon patent infringement case(Yahoo Finance)
2024-04-29 03:55
Sector Update: Health Care Stocks Edge Higher Late Afternoon(Yahoo Finance)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.